+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030- Product Image
Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5613065
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Therapeutic Vaccines Market grew from USD 33.05 billion in 2024 to USD 36.60 billion in 2025. It is expected to continue growing at a CAGR of 10.45%, reaching USD 60.02 billion by 2030.

Defining the New Era of Therapeutic Vaccines

Therapeutic vaccines are redefining the intersection of immunology and personalized medicine, offering targeted interventions that harness the body’s immune response to combat established diseases. Unlike prophylactic vaccines designed to prevent illness, therapeutic vaccines aim to treat existing conditions by stimulating or modulating immune cell activity. This approach holds promise for a range of chronic and life-threatening diseases, from autoimmune disorders to various cancers.

The growing scientific understanding of antigen presentation, tumor immunology, and viral pathogenesis has fueled a surge of innovation in vaccine design and delivery. Advances in genomic sequencing, bioinformatics, and novel delivery platforms are unlocking opportunities to tailor therapeutic vaccines to individual patient profiles. As regulatory frameworks adapt and clinical trial designs become more flexible, the path from discovery to market is accelerating, creating an environment ripe for investment and strategic partnerships.

Pivotal Transformations Reshaping Vaccine Development

A convergence of scientific breakthroughs and shifting market dynamics is transforming therapeutic vaccines from niche research projects into viable commercial offerings. Revolutionary technologies such as mRNA platforms and viral vectors have demonstrated their applicability beyond infectious disease prevention, proving their capacity to address oncological and chronic conditions. This transition has been driven by compelling clinical data, expanding immuno-oncology pipelines, and growing confidence among investors and pharmaceutical companies.

Concurrently, regulatory bodies worldwide are streamlining approval pathways for advanced therapies, implementing adaptive trial designs that balance rigorous safety assessments with accelerated timelines. Government incentives and public-private partnerships are further stimulating innovation, particularly in areas of high unmet medical need. As a result, the competitive landscape is evolving rapidly, with a new generation of biotechs and established players vying to deliver the first wave of commercially successful therapeutic vaccines.

Assessing the Toll of 2025 U.S. Tariffs on Therapeutic Vaccines

The introduction of new tariffs in the United States during 2025 has imposed a significant recalibration across the therapeutic vaccines supply chain. Increased duties on critical raw materials and excipients have elevated production costs, prompting manufacturers to reassess sourcing strategies and negotiate alternative supplier agreements. These financial pressures have, in some cases, delayed clinical trial initiations and prompted adjustments to pricing models.

As policymakers and industry leaders grapple with the broader implications, companies are exploring regional diversification to mitigate risks. Shifting certain manufacturing and fill-finish operations to lower-tariff jurisdictions has emerged as a tactical response, albeit one that requires careful evaluation of regulatory compatibility and logistical complexity. Ultimately, the cumulative impact of these tariffs underscores the need for agile supply chain management and proactive engagement with trade policymakers to preserve market momentum.

Unveiling Market Segmentation to Drive Strategic Focus

A nuanced understanding of market segmentation offers critical guidance for resource allocation and portfolio optimization. Analysis by indication reveals that autoimmune diseases represent a foundational pillar of therapeutic vaccine development, where conditions like lupus, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes present distinct immunological targets and clinical endpoints. Cancer indications, encompassing breast, cervical, colorectal malignancies, melanoma, and prostate neoplasms, command substantial R&D investment as immuno-oncology strategies continue to demonstrate durable responses. Infectious disease vaccines targeting cytomegalovirus, hepatitis viruses, HIV, human papillomavirus, and seasonal influenza remain essential for both prophylactic and therapeutic purposes, while emerging efforts in neurological disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis, epilepsy, and Parkinson’s disease, highlight the expanding frontiers of immunotherapy.

Equally vital is the technology platform dimension, where dendritic cell vaccines leverage antigen-presenting cell biology for precise immune activation. DNA-based approaches, primarily plasmid constructs, offer stability and ease of manufacturing, whereas peptide vaccines capitalize on defined epitopes to elicit targeted T-cell responses. RNA platforms, including messenger RNA and self-amplifying RNA, have gained prominence for their rapid design and scalable production. Viral vector systems such as adenovirus, lentivirus, and vaccinia virus enable robust antigen delivery, and whole-cell platforms continue to provide complex antigenic repertoires for broad immune engagement.

Administration routes-ranging from intradermal and intramuscular injections to intravenous infusions and subcutaneous deliveries-must be tailored to therapeutic context, balancing immunogenicity with patient convenience. Distribution channels encompass hospital pharmacies, online pharmacies, and retail pharmacies, each with unique storage, handling, and regulatory considerations. End users include clinics, hospitals, and research institutes, where integration of vaccine administration into existing care pathways demands careful coordination with healthcare providers and payers.

Regional Dynamics Shaping Therapeutic Vaccine Adoption

The Americas region continues to lead in therapeutic vaccine innovation, supported by robust biotech funding, world-class research institutions, and an adaptive regulatory environment. North America, in particular, benefits from significant venture capital activity and ample clinical trial infrastructure, propelling novel candidates through the development pipeline. Latin America presents emerging opportunities as governments expand immunization programs and invest in local manufacturing capabilities.

In Europe, Middle East, and Africa, the landscape is shaped by diverse regulatory frameworks and access challenges. The European Union’s harmonized approval processes offer predictable pathways for multinational launches, while the Middle Eastern and African markets are characterized by selective capacity building and strategic partnerships to address local disease burdens. Stakeholders are increasingly focused on establishing regional centers of excellence to accelerate clinical research and improve distribution networks.

Asia-Pacific is witnessing accelerated adoption of therapeutic vaccines, driven by growing healthcare expenditures and a strong commitment to biotechnology innovation. Countries such as China, Japan, South Korea, and India are investing heavily in domestic R&D, supported by government initiatives to promote advanced therapy medicinal product development. Collaborative ventures between multinational corporations and local biotechs are enhancing market access and facilitating technology transfer, establishing Asia-Pacific as a critical growth engine.

Competitive Landscape and Leading Innovators

The competitive landscape is marked by a diverse array of players, from emerging biotech firms pioneering first-in-class candidates to global pharmaceutical leaders with established oncology and infectious disease portfolios. Strategic partnerships and licensing agreements have become commonplace, with companies aligning their strengths in antigen discovery, platform technology, and clinical development to accelerate time to market. Key innovators are focusing on platform scalability, leveraging automation and high-throughput screening to optimize candidate selection.

Dedicated immuno-oncology ventures have reported positive early-stage data, prompting larger organizations to pursue bolt-on acquisitions and equity investments. Collaboration between academic research centers and industry sponsors continues to yield breakthroughs in antigen identification, adjuvant design, and immune monitoring. Manufacturers are also forming alliances with contract development and manufacturing organizations to secure capacity for both vector-based and cell-based vaccine platforms.

As market entry barriers evolve, intellectual property strategies are shifting toward broader patent estates covering antigen constructs, delivery modalities, and combination regimens. Companies with strong regulatory track records are leveraging their experience to navigate complex approval processes in multiple jurisdictions, while those emphasizing safety and cost-effectiveness are exploring novel partnerships to facilitate early access and real-world evidence generation.

Strategic Imperatives for Leading in a Competitive Market

Industry leaders must prioritize platform versatility to respond swiftly to diverse therapeutic targets and emerging pathogen threats. Integrating advanced analytics into candidate selection processes will enhance the predictive power of preclinical models, reducing attrition rates and accelerating advancement to clinical trials. Strategic investments in modular manufacturing facilities can provide the agility to pivot between different vaccine formats and meet fluctuating demand.

Robust stakeholder engagement is essential for building confidence among regulators, payers, and healthcare providers. Early collaboration with regulatory authorities can streamline trial designs and expedite approval pathways, while transparent communication of safety and efficacy data fosters trust. Generating real-world evidence through post-launch studies will support reimbursement negotiations and demonstrate long-term value to payers.

Forming cross-sector partnerships will expand access to complementary capabilities, from antibody discovery to digital health solutions for patient monitoring and adherence. Leaders should explore flexible pricing models that reflect therapeutic value and patient outcomes, ensuring affordability without compromising innovation incentives. Finally, cultivating talent with expertise across immunology, bioengineering, and data science will sustain a culture of innovation and drive future breakthroughs.

Rigorous Methodology Underpinning Our Insights

This report is grounded in a comprehensive research framework that integrates secondary and primary data sources. Secondary research included an exhaustive review of scientific literature, regulatory filings, investor presentations, and company financial reports. Databases and industry registries provided quantitative insights into trial counts, approval timelines, and patent landscapes.

Primary research comprised in-depth interviews with industry executives, academic researchers, clinical investigators, and regulatory experts. Insights gathered during these discussions were systematically validated and triangulated against secondary data to ensure accuracy and relevance. The segmentation analysis leverages a multi-dimensional approach, covering indication, technology platform, administration route, distribution channel, and end user, to deliver a holistic market perspective.

All findings have undergone rigorous quality checks, and methodologies have been transparently documented to guarantee reproducibility. Limitations related to emerging therapeutic modalities and evolving regulatory standards have been acknowledged, with recommendations provided to address areas of uncertainty and future research needs.

Concluding Perspectives on the Future of Therapeutic Vaccines

The therapeutic vaccines market stands at an inflection point, driven by remarkable scientific progress, strategic collaborations, and evolving regulatory frameworks. Breakthroughs in platform technologies and antigen discovery are expanding the scope of treatable conditions, while adaptive trial designs and incentive programs are accelerating the path to approval. At the same time, external factors such as trade policies and supply chain dynamics underscore the importance of operational resilience.

Companies that embrace flexibility in manufacturing, invest in robust stakeholder engagement, and cultivate cross-disciplinary expertise will be best positioned to capture emerging opportunities. As the market matures, real-world evidence and value-based pricing will become increasingly critical to sustain reimbursement support and patient access. Ultimately, the successful commercialization of therapeutic vaccines will rely on a coordinated effort among developers, regulators, payers, and healthcare providers.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Autoimmune Diseases
      • Lupus
      • Multiple Sclerosis
      • Rheumatoid Arthritis
      • Type 1 Diabetes
    • Cancer
      • Breast Cancer
      • Cervical Cancer
      • Colorectal Cancer
      • Melanoma
      • Prostate Cancer
    • Infectious Diseases
      • CMV
      • Hepatitis
      • HIV
      • HPV
      • Influenza
    • Neurological Disorders
      • Alzheimer's Disease
      • Amyotrophic Lateral Sclerosis
      • Epilepsy
      • Parkinson's Disease
  • Technology Platform
    • Dendritic Cell
    • DNA
      • Plasmid
    • Peptide
    • RNA
      • mRNA
      • Self Amplifying RNA
    • Viral Vector
      • Adenovirus
      • Lentivirus
      • Vaccinia Virus
    • Whole Cell
  • Administration Route
    • Intradermal
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Clinics
    • Hospitals
    • Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • BioNTech SE
  • Bavarian Nordic A/S
  • Agenus Inc.
  • Inovio Pharmaceuticals, Inc.
  • Dendreon Pharmaceuticals LLC
  • GeoVax Labs, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Therapeutic Vaccines Market, by Indication
8.1. Introduction
8.2. Autoimmune Diseases
8.2.1. Lupus
8.2.2. Multiple Sclerosis
8.2.3. Rheumatoid Arthritis
8.2.4. Type 1 Diabetes
8.3. Cancer
8.3.1. Breast Cancer
8.3.2. Cervical Cancer
8.3.3. Colorectal Cancer
8.3.4. Melanoma
8.3.5. Prostate Cancer
8.4. Infectious Diseases
8.4.1. CMV
8.4.2. Hepatitis
8.4.3. HIV
8.4.4. HPV
8.4.5. Influenza
8.5. Neurological Disorders
8.5.1. Alzheimer's Disease
8.5.2. Amyotrophic Lateral Sclerosis
8.5.3. Epilepsy
8.5.4. Parkinson's Disease
9. Therapeutic Vaccines Market, by Technology Platform
9.1. Introduction
9.2. Dendritic Cell
9.3. DNA
9.3.1. Plasmid
9.4. Peptide
9.5. RNA
9.5.1. mRNA
9.5.2. Self Amplifying RNA
9.6. Viral Vector
9.6.1. Adenovirus
9.6.2. Lentivirus
9.6.3. Vaccinia Virus
9.7. Whole Cell
10. Therapeutic Vaccines Market, by Administration Route
10.1. Introduction
10.2. Intradermal
10.3. Intramuscular
10.4. Intravenous
10.5. Subcutaneous
11. Therapeutic Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Therapeutic Vaccines Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Research Institutes
13. Americas Therapeutic Vaccines Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Therapeutic Vaccines Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Therapeutic Vaccines Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Pfizer Inc.
16.3.3. GlaxoSmithKline plc
16.3.4. Moderna, Inc.
16.3.5. BioNTech SE
16.3.6. Bavarian Nordic A/S
16.3.7. Agenus Inc.
16.3.8. Inovio Pharmaceuticals, Inc.
16.3.9. Dendreon Pharmaceuticals LLC
16.3.10. GeoVax Labs, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THERAPEUTIC VACCINES MARKET MULTI-CURRENCY
FIGURE 2. THERAPEUTIC VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. THERAPEUTIC VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 90. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 91. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 92. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 93. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 94. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 95. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 96. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 97. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 98. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 102. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 103. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 104. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 106. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 107. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 108. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 109. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 163. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 164. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 167. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 168. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 169. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 170. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 171. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 175. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 176. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 177. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 179. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 180. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 181. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 182. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 199. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 200. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 201. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 203. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 204. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 205. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 206. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 211. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 212. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 213. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 215. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 216. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 217. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 218. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 219. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 259. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 260. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 261. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 262. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 263. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 264. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 265. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 266. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 267. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 283. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 284. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 285. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 286. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 287. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 288. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 289. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 290. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 291. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 295. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 296. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 297. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 298. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 299. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 300. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 301. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 302. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 303. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 307. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 308. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 309. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 310. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 311. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 312. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 313. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 314. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 318. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 319. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 320. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 321. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 322. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 323. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 324. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2030 (USD MILLION)
TABLE 325. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 326. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 327. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 330. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 331. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 332. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 333. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 334. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 335. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2030 (USD MILLION)
TABLE 336. EGY

Companies Mentioned

The companies profiled in this Therapeutic Vaccines market report include:
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • BioNTech SE
  • Bavarian Nordic A/S
  • Agenus Inc.
  • Inovio Pharmaceuticals, Inc.
  • Dendreon Pharmaceuticals LLC
  • GeoVax Labs, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 36.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 60.02 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Therapeutic Vaccines - Global Strategic Business Report - Product Image

Therapeutic Vaccines - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Global Therapeutic Vaccines Market: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Global Therapeutic Vaccines Market: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 300 Pages
  • Global
From
Therapeutic Vaccines Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography - Product Image

Therapeutic Vaccines Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography

  • Report
  • 207 Pages
  • Global
From
2024 Global Forecast for Therapeutic Vaccines Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Therapeutic Vaccines Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From

About the Therapeutic Vaccine Market

The Therapeutic Vaccine market is a subset of the Vaccines market, focusing on the development of vaccines to treat existing diseases. These vaccines are designed to stimulate the body's immune system to fight off existing infections, rather than prevent them. Therapeutic Vaccines are used to treat a variety of diseases, including cancer, HIV, and hepatitis. They are also used to treat autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Therapeutic Vaccines are typically administered in a series of doses, and may require additional booster shots to maintain their effectiveness. They are often used in combination with other treatments, such as chemotherapy or radiation therapy. Companies in the Therapeutic Vaccine market include Merck, GlaxoSmithKline, Sanofi, Pfizer, and Johnson & Johnson. Other companies, such as Moderna and Novavax, are also developing therapeutic vaccines. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.